Tüdőrák: vizsgálatok itt: Olaszország

In Olaszország 272 Also abroad 2746

272 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 14.. Ask the study team whether a trial fits you.

3. fázisTaking people
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Where
Milan, Monza, Orbassano, Padova, Rozzano
Életkor
18 év and over
People
400 worldwide
Run by
AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00
3. fázisTaking people
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Where
Aviano, Bari, Brescia, Florence, Meldola, Orbassano, Padova, Parma, Rome, Verona
Életkor
18 év and over
People
670 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00
3. fázisTaking people
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Where
Bergamo, Brescia, Candiolo, Meldola, Milan, Pavia, Peschiera del Garda
Életkor
18 év and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680790 · EU 2026-526486-21-00
1/2. fázisTaking people
A Study of DS-3939a in Participants With Solid Tumors
Where
Milan, Orbassano, Pavia, Perugia, Ravenna, Rome
Életkor
18 év and over
People
400 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07739966 · EU 2026-525218-75-00
1. fázisTaking people
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Where
Candiolo, Milan, Naples, Rozzano
Életkor
18 év and over
People
15 worldwide
Run by
Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00
3. fázisTaking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Bari, Bergamo, Florence, Milan, Naples, Palermo, Peschiera del Garda, Ravenna, Rome, Siena
Életkor
18 év and over
People
1000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
3. fázisTaking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Catanzaro, Milan, Naples, Padova, Ravenna, Rome, Verona
Életkor
18 év and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
1/2. fázisTaking people
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Where
Florence, Meldola, Milan, Rome
Életkor
18 év to 64 év
People
170 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07227597 · EU 2025-521032-11-00
3. fázisTaking people
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Where
Bergamo, Florence, Milan, Novara, Perugia, Rome
Életkor
18 év and over
People
876 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Bergamo, Florence, Milan, Modena, Monza, Perugia, Peschiera del Garda, Rome, Turin
Életkor
18 év and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
3. fázisTaking people
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Where
Aviano, Bergamo, Bologna, Catania, Fano, Florence, Genoa, Meldola, Milan, Monza, Orbassano, Padova, Parma, Ravenna, Rome, Rozzano, Verona
Életkor
18 év and over
People
356 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566052 · EU 2025-524079-22-00
1/2. fázisTaking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Ancona, Bari, Milan, Padova, Ravenna, Rome
Életkor
12 év and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
3. fázisTaking people
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Where
Alexandria, Padova, Perugia, Rome, Siena, Verona
Életkor
18 év and over
People
290 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT06284317 · EU 2023-508773-82-00
3. fázisTaking people
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Where
Milan, Monza, Naples, Orbassano, Parma, Perugia, Pisa, Rome, Rozzano, Verona
Életkor
18 év and over
People
590 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00
No phaseTaking people
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Where
Acquaviva Delle Fonti, Bergamo, Fano (PU), Genoa, Lecce, Mestre, Milan, Misterbianco (CT), Modena, Naples, Novara, Palermo, Ravenna, Rome, Sassari, Trento, Verona
Életkor
18 év and over
People
700 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07284121
1/2. fázisTaking people
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Where
Meldola, Milan, Orbassano, Rome
Életkor
18 év and over
People
320 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Aviano, Genoa, Livorno, Milan, Misterbianco (CT), Modena, Monza MI, Naples, Pesaro, Peschiera Del Garda (VR), Rome, Statte, Trento
Életkor
18 év and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
3. fázisTaking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Aviano, Bergamo, Caserta, Florence, Genoa, Milan, Napoli, Ravenna, Rome, Verona
Életkor
18 év and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
3. fázisTaking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Aviano, Milan, Naples, Orbassano, Parma, Ravenna, Rome
Életkor
18 év and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
1/2. fázisTaking people
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Where
Milan, Orbassano, Padova, Parma, Ravenna, Rome
Életkor
18 év and over
People
160 worldwide
Run by
TRIANA Biomedicines, Inc.
See details and how to joinNCT07491497 · EU 2025-524418-27-00
No phaseTaking people
Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer
Where
Pavia
Életkor
18 év and over
People
180
Run by
Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT05384873
3. fázisTaking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Bari, Bologna, Catania, Milan, Naples, Padova, Rome, Varese, Verona
Életkor
18 év and over
People
1264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
1. fázisTaking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Milan
Életkor
18 év and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
3. fázisTaking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Avellino, Aviano, Bologna, Florence, Lecce, Meldola, Milan, Orbassano, Padova, Palermo, Rome, Rozzano, Verona
Életkor
18 év and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
3. fázisTaking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Bari, Catania, Genova, Meldola, Milan, Monza, Naples, Orbassano, Rome, Verona
Életkor
18 év and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00